×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Novacap Acquires Integral Ad Science for $1.9 Billion in an All-Cash Deal

  • September 24, 2025

Novacap - Integral Ad Science Merger

Integral Ad Science Holding Corp. (IAS) entered a merger agreement on September 24, 2025, to be acquired by Novacap in an all-cash deal valued at $1.9 billion.

Deal Structure:

Novacap will acquire all of the outstanding shares of Integral Ad Science for $10.3 per share in cash, representing a premium of 21.75% from the stock’s last close.

Company Profile:

Integral Ad Science is a global digital advertising verification and measurement company that helps advertisers, publishers, and platforms ensure ads are viewable, fraud-free, brand-safe, and optimized across devices and channels.

Novacap is a private equity firm with over $10 billion in assets under management, partnering with entrepreneurs and management teams to grow middle-market companies across technology, digital infrastructure, industries, and financial services.

Deal Details and Timeline:

As part of the transaction, current shareholder Vista Equity Partners will exit its investment upon closing.

The deal is expected to close before the end of 2025.

After the deal closes, Integral Ad Science will continue to use its name and brand.

Jefferies served as financial advisor and Kirkland & Ellis as legal counsel to Integral Ad Science. At the same time, Evercore provided financial advice, and Willkie Farr & Gallagher served as legal counsel to Novacap.

Novacap is acquiring Integral Ad Science at 2.91 times the sales.

Deal Metrics:

For a more detailed insight into this merger and acquisition transaction, please refer to the Deal Metrics page:

Deal Metrics for the acquisition of Integral Ad Science Holding Corp. (IAS) by Novacap

The Deal Metrics page for each merger or acquisition includes:

  • A spread history chart of the merger from announcement through eventual completion or failure.
  • Each event as the merger progresses through the HSR period, various regulatory approvals, shareholder votes, etc.
  • News and SEC filings.
  • A history of deal updates.
  • And much more.

Disclaimer: Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article